EAR2 Activators

EAR2, a member of the estrogen-related receptor (ERR) family, plays a crucial role in diverse physiological processes, including energy metabolism and cell differentiation. The chemicals identified as potential EAR2 activators exert their effects by modulating the ERR signaling pathway, specifically targeting ERRα, ERRβ, and ERRγ. These inverse agonists alleviate the inhibitory effects of ERRs on EAR2 transcriptional activity, leading to enhanced EAR2 expression and activation. GSK4716, a selective inverse agonist for ERRγ, relieves the inhibitory effect of ERRγ on EAR2 transcriptional activity, indirectly activating EAR2. Similarly, DY131, a selective inverse agonist of ERRα, mitigates the suppressive effects of ERRα on EAR2 transcriptional activity, contributing to enhanced EAR2 expression. XCT790, a specific inverse agonist for ERRα, alleviates the inhibitory effect of ERRα on EAR2, leading to increased EAR2 transcriptional activity.

C29, an inverse agonist for ERRγ, counteracts the inhibitory effects of ERRγ on EAR2 transcriptional activity, indirectly enhancing EAR2 expression. XCT-31, a selective inverse agonist for ERRβ, mitigates the inhibitory effects of ERRβ on EAR2, contributing to increased EAR2 transcriptional activity. The compound with CAS number 313967-18-9, another selective inverse agonist for ERRγ, relieves the suppressive effects of ERRγ on EAR2 transcriptional activity, indirectly activating EAR2. Collectively, these chemicals represent a class of compounds that can specifically activate EAR2 by targeting the ERR signaling pathway. Understanding the regulatory mechanisms of EAR2 and its modulation by these activators provides valuable insights into the intricate control of transcriptional activities involved in cellular processes. The identified compounds offer a diverse set of tools for further investigations into the functional roles of EAR2 and its potential implications in various physiological and pathological conditions.